Market Performance - The three major indices experienced cumulative gains this week, with the Shanghai Composite Index rising by 0.84%, the Shenzhen Component Index increasing by 4.36%, and the ChiNext Index up by 7.74% [1] - Over 1,700 stocks saw price increases, particularly in the chip, semiconductor, and rare earth permanent magnet sectors [1] Index Details - Shanghai Composite Index: +0.37%, closing at 3,828 points with a trading volume of 1,221.7 billion [3] - Shenzhen Component Index: +0.99%, closing at 12,696 points with a trading volume of 1,576.6 billion [3] - ChiNext Index: +2.23%, closing at 2,890 points with a trading volume of 763.8 billion [3] Notable Stocks - The stock "Kaipu Cloud" surged by 133.74%, leading the gains, while 33 stocks increased by over 30% this week [4][5] - The communication sector had the highest number of stocks with over 30% gains, totaling 6 stocks, followed by the computer sector with 5 stocks [4] Trading Activity - 80 stocks had a turnover rate exceeding 100%, with "Chuanrun Shares" leading at 229.85% [6][7] - The computer, basic chemicals, machinery, and communication sectors had a significant presence among stocks with high turnover rates [6] Fund Flows - No industry saw net inflows from major funds this week, with 11 industries experiencing net outflows exceeding 10 billion [8] - "Gaoer Shares" received the highest net inflow at 1.921 billion, while "Langchao Information" faced the largest net outflow at 3.241 billion [8] Margin Trading - "Shenghong Technology" topped the list for net margin purchases with 4.528 billion, followed by "Hanwuji-U" and "Zhongxin International" with 3.031 billion and 2.868 billion respectively [11][12] Institutional Research - "Mairui Medical" attracted the most attention from institutions, with 397 institutions participating in its research [13][14] - The sectors of focus for institutional research included pharmaceuticals, electronic components, chemicals, and photovoltaics [13] New Institutional Interests - 131 stocks received initial attention from institutions this week, with "Yangnong Chemical" receiving a "Buy" rating and a target price of 93.52 yuan [16][17] - Other stocks like "Tai Ling Micro" and "Dazhu CNC" also garnered initial interest from multiple institutions [16]

Group 1: Economic Transition - The Chinese economy is shifting from a resource-driven growth model to an innovation-driven one, reflecting a structural change in the economy [1] - The integration of new and traditional economies is forming a more robust growth structure [1] Group 2: AI Industry Performance - The AI sector has become a strong market driver, with significant performance growth rooted in actual earnings rather than mere expectations [2] - The computer, electronics, and communication industries reported substantial net profit increases, with respective growth rates of 40.54%, 27.57%, and 7.81% [2] - AI chip leader Cambricon Technologies saw a revenue surge of 4347.82% year-on-year, reaching 2.881 billion yuan, and turned a profit of 1.038 billion yuan after a loss in the previous year [2] Group 3: Traditional Industry Recovery - The "anti-involution" policy has revitalized traditional industries, leading to profit recovery across various sectors [4] - The steel and agriculture sectors reported net profits of 13.137 billion yuan and 27.411 billion yuan, with year-on-year growth rates of 157.17% and 166.72% respectively [4] - Shandong Steel achieved a revenue of 36.806 billion yuan, a year-on-year increase of 118.60%, and turned a profit of 12.5258 million yuan [4] Group 4: Market Signals and Future Outlook - Companies are providing positive signals for future performance, with medical device company Mindray Medical projecting revenue growth in Q3 2025 [7] - Mindray anticipates overall revenue growth and improved performance in both domestic and international markets [7] - Lixun Precision is expected to report a net profit of 10.89 billion to 11.344 billion yuan for the first three quarters of 2025, reflecting a year-on-year increase of 20% to 25% [8]

深圳迈瑞生物医疗电子股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 证券代码：300760 证券简称：迈瑞医疗 公告编号：2025-034 深圳迈瑞生物医疗电子股份有限公司（下称"本公司"或"公司"）2025年第二次中期 权益分派方案已获2025年8月27日召开的第八届董事会第十三次会议审议通过，在公司2024 年年度股东大会决议授权范围内，无需再次提交股东会审议。现将权益分派事宜公告如下： 一、股东会及董事会审议通过利润分配方案等情况 年第一次中期利润分配预案及提请股东大会授权董事会制定2025年其他中期分红方案的议 案》，同意授权董事会根据股东大会决议在符合利润分配的条件下制定其他具体的2025年中 期分红方案。公司于2025年8月27日召开第八届董事会第十三次会议，审议通过了《关于2025 年第二次中期利润分配方案的议案》，2025年第二次中期利润分配方案为：以公司2025年6 月30日的总股本1,212,441,394股为基数，向全体股东每10股派发现金股利人民币13.10元（含 税），共计派发现金股利人民币1,588,298,226.1 ...

证券研究报告 | 金融工程 2025 年 08 月 29 日 成长驱动+龙头集中，创业板综指彰显投资潜力 ——银华创业板综合 ETF 投资价值分析 作为全面反映创业板整体表现的核心宽基指数，创业板综指在我国新经济领域 具有较强代表性。指数成分股覆盖新能源、医药、电子、通信等战略性新兴产 业，兼具成长性与产业龙头集中度。在全球产业升级和国内创新驱动背景下， 创业板综指展现出优于主流宽基指数的收益弹性。 任瞳 S1090519080004 rentong@cmschina.com.cn ❑ 风险提示：本报告仅作为投资参考，基金产品过往业绩并不预示其未来表 现，亦不构成投资收益的保证或投资建议，新发基金无历史业绩可参考。 敬请阅读末页的重要说明 专题报告 ❑ 成长驱动，产业空间广阔：创业板综指汇聚了新能源、锂电池、光伏、半 导体、医疗器械等新兴产业龙头企业，具备长期成长动能。受益于能源转 型、人口老龄化及数字化经济等趋势，相关产业在国内外市场空间仍在快 速扩张。 ❑ 权重集中度适中，龙头效应显著 ：指数前十大权重股合计占比约 24.55%，其中宁德时代、东方财富、迈瑞医疗等行业龙头具备全球竞争 力，体现出创业板在关 ...

Core Viewpoint - In the first half of 2025, Mindray Medical reported a significant decline in revenue and net profit, primarily due to domestic market challenges and intensified competition in the medical device sector [1][2][3] Financial Performance - Revenue for the first half of 2025 was approximately 16.743 billion yuan, a year-on-year decrease of 18.45% - Net profit was around 5.069 billion yuan, down 32.96% - Operating cash flow decreased by 53.83% to about 3.922 billion yuan [1] Business Segments - The in-vitro diagnostics (IVD) segment generated revenue of approximately 6.424 billion yuan, a decline of 16.11%, with a gross margin decrease of 4.37% to 59.5% - The medical imaging segment reported revenue of 3.312 billion yuan, down 22.51% - The life information and support segment had revenue of 5.479 billion yuan, a decrease of 31.59% [2][3] Domestic Market Challenges - Domestic business faced a decline of over 30%, attributed to healthcare reform, industry regulation, and oversupply during the pandemic - The company anticipates a market recovery starting in Q3 2025, with improved revenue growth expected [1][2] International Business Growth - International revenue accounted for approximately 50% of total revenue, with a year-on-year growth of 5.39% - The international IVD business experienced double-digit growth, while the international medical imaging segment saw mid-single-digit growth [3][4] Future Outlook - The company believes the most challenging period for domestic operations has passed and is focusing on market share growth, particularly in the IVD sector - Mindray is investing in high-value consumables and international markets, expecting significant growth in these areas [2][4] R&D and Financial Position - R&D expenditure for the first half of 2025 was 1.777 billion yuan, representing 10.61% of revenue - As of June 30, 2025, the company held cash and cash equivalents of approximately 16.967 billion yuan [4]

根据调研日期截止日统计，近10日（8月18日至8月29日），海外机构对230家上市公司进行调研，其 中，天孚通信最受关注，被59家海外机构密集调研。 证券时报·数据宝统计显示，近10日共有572家公司获机构调研，调研机构类型显示，证券公司调研达 557家，占比最多；基金公司调研486家，位列其后；海外机构共对230家上市公司进行走访。 海外机构调研榜单中，天孚通信参与调研的海外机构达到59家，最受关注；其次是迈瑞医疗，参与调研 的海外机构共有56家。 从股价表现看，获海外机构调研股近10日平均上涨7.77%。其中，股价上涨的有天孚通信、剑桥科技 等，表现最好的是天孚通信，累计涨幅为84.05%。股价下跌的有62只，跌幅最大的是三德科技，累计 跌幅为13.59%。 从业绩来看，近日获海外机构关注个股中，有187只公布了中期业绩（含快报），净利润增幅居前的有 索通发展、完美世界。 公布中期业绩预告的个股有5只，业绩预告类型来看，预增3只，预降2只。以业绩预告净利润增幅中值 统计，净利润增幅最高的是纳睿雷达，中期净利润同比增长幅度为860.00%。 近10日海外机构调研股 | 证券代码 | 证券简称 | 海外机构家 ...

证券研究报告 迈瑞医疗 (300760 CH) 2Q 收入边际向好，期待 3Q 迎来拐点 | | | 2025 年 8 月 29 日│中国内地 医疗器械 公司 1H25 实现收入 167.43 亿元（yoy-18.4%）、归母净利 50.69 亿元 （yoy-33.0%）、扣非归母净利 49.49 亿元（yoy-32.9%），业绩基本符合 我们预期；其中公司 2Q25 收入 qoq+3.3%，整体收入边际向好。公司预计 3Q25 整体收入将实现同比正增长，并延续单季度收入逐季环比改善趋势。 考虑公司业务布局全面，国内市场需求持续复苏且海外市场推广积极推进， 公司业务长期成长空间明确。维持"买入"评级。 积极强化销售推广及研发投入，持续筑高竞争壁垒 公司 1H25 毛利率为 61.7%（yoy-2.8pct），我们推测主因国内行业外部因 素短期扰动。公司 1H25 销售/管理/研发费用率分别为 14.5%/4.1%/9.6% （yoy+1.9/+0.1/+0.9pct），公司持续巩固销售推广及研发投入强度，持续 提升行业竞争力。 公司三大核心业务长期成长空间明确 1）IVD：1H25 收入 64.24 亿元（y ...

Investment Rating - The report maintains a "Buy" rating for the company with a target price of RMB 300, indicating a potential upside of 21% from the current price of RMB 247.08 [1][2]. Core Insights - The company's performance in 1H25 was significantly under pressure, with revenue of RMB 16.7 billion, a year-on-year decrease of 18%, and a net profit of RMB 4.9 billion, down 33% year-on-year. However, there is a clear expectation for revenue recovery starting in 3Q25, with projected positive year-on-year growth [1][8]. - The report anticipates that the recovery in domestic equipment bidding projects will gradually convert into revenue, leading to further revenue growth in 4Q25. The low base effect from the previous year is expected to accelerate revenue and net profit growth in 2026 [1][8]. Financial Performance and Forecast - The company's revenue and net profit forecasts for the upcoming years are as follows: - Revenue: RMB 34.93 billion in 2023, RMB 36.73 billion in 2024, RMB 37.08 billion in 2025E, RMB 45.94 billion in 2026E, and RMB 53.25 billion in 2027E, with year-on-year growth rates of 15.0%, 5.1%, 1.0%, 23.9%, and 15.9% respectively [2][10]. - Net profit: RMB 11.58 billion in 2023, RMB 11.67 billion in 2024, RMB 11.39 billion in 2025E, RMB 14.49 billion in 2026E, and RMB 17.40 billion in 2027E, with year-on-year growth rates of 20.6%, 0.7%, -2.4%, 27.2%, and 20.1% respectively [2][10]. - The report highlights that the company's international revenue is expected to continue to grow, with a projected double-digit growth rate for the second half of 2025 [1][8]. Segment Analysis - Domestic revenue saw a significant decline of 33% in 1H25, primarily due to prolonged weak bidding conditions for equipment, while international revenue grew by 5%, now accounting for 50% of total revenue [8]. - The report notes that the IVD segment experienced a 16% decline in revenue, attributed to price reductions from centralized procurement and a decrease in testing volumes due to policy changes. However, international IVD business showed resilience with a 12% growth [8].

Group 1 - Hailiang Co., Ltd. achieved a revenue of 44.476 billion yuan, a year-on-year increase of 1.17%, and a net profit of 711 million yuan, a year-on-year increase of 15.03% [1] - Yinfai Storage reported a revenue of 543 million yuan, a year-on-year decrease of 18.97%, and a net profit of 62.347 million yuan, a year-on-year decrease of 20.05% [1] - Huamao Technology achieved a revenue of 1.108 billion yuan, a year-on-year increase of 14.42%, and a net profit of 137 million yuan, a year-on-year increase of 3.21% [2] Group 2 - Postal Savings Bank reported a revenue of 179.446 billion yuan, a year-on-year increase of 1.5%, and a net profit of 49.228 billion yuan, a year-on-year increase of 0.85% [4] - Bright Dairy achieved a revenue of 12.472 billion yuan, a year-on-year decrease of 1.9%, and a net profit of 217 million yuan, a year-on-year decrease of 22.53% [6] - Pianzaihuang reported a revenue of 5.379 billion yuan, a year-on-year decrease of 4.81%, and a net profit of 1.442 billion yuan, a year-on-year decrease of 16.22% [7] Group 3 - Great Wall Motors achieved a revenue of 92.335 billion yuan, a year-on-year increase of 0.99%, and a net profit of 6.337 billion yuan, a year-on-year decrease of 10.21% [9] - Haowei Group reported a revenue of 13.956 billion yuan, a year-on-year increase of 15.42%, and a net profit of 2.028 billion yuan, a year-on-year increase of 48.34% [10] - Batian Co., Ltd. achieved a revenue of 2.543 billion yuan, a year-on-year increase of 63.93%, and a net profit of 456 million yuan, a year-on-year increase of 203.71% [12] Group 4 - Yuxin Technology reported a revenue of 1.415 billion yuan, a year-on-year decrease of 5.01%, and a net profit of 220 million yuan, a year-on-year increase of 35.26% [14] - Zhongti Industry reported a revenue of 787 million yuan, a year-on-year decrease of 25.24%, and a net loss of 24.3955 million yuan [15] - Kemei Diagnostics achieved a revenue of 165 million yuan, a year-on-year decrease of 27.03%, and a net profit of 24.3408 million yuan, a year-on-year decrease of 68.24% [16] Group 5 - Huatai Co., Ltd. reported a revenue of 6.409 billion yuan, a year-on-year decrease of 1.86%, and a net profit of 67.6382 million yuan, a year-on-year decrease of 63.13% [17] - Fudan Fuhua reported a revenue of 326 million yuan, a year-on-year increase of 2.20%, and a net loss of 711.58 million yuan [19] - Haili Co., Ltd. achieved a revenue of 12.426 billion yuan, a year-on-year increase of 13.16%, and a net profit of 333.546 million yuan, a year-on-year increase of 693.76% [21] Group 6 - Xintong New Science reported a revenue of 61.852 million yuan, a year-on-year increase of 8.49%, and a net loss of 30.393 million yuan [22] - Newzhisoft achieved a revenue of 897 million yuan, a year-on-year decrease of 3.40%, and a net profit of 30.3531 million yuan, a year-on-year increase of 42.84% [24] - Maolai Optics reported a revenue of 319 million yuan, a year-on-year increase of 32.26%, and a net profit of 32.7555 million yuan, a year-on-year increase of 110.36% [25] Group 7 - Qianjin Pharmaceutical achieved a revenue of 1.818 billion yuan, a year-on-year decrease of 5.52%, and a net profit of 128 million yuan, a year-on-year increase of 8.50% [28] - Quanfeng Automotive reported a revenue of 1.218 billion yuan, a year-on-year increase of 18.90%, and a net loss of 167 million yuan [29] - Zhongjin Lingnan's application for a specific issuance of A-shares has been accepted by the Shenzhen Stock Exchange [31] Group 8 - Zhonglv Electric achieved a revenue of 2.333 billion yuan, a year-on-year increase of 29.30%, and a net profit of 618 million yuan, a year-on-year increase of 33.06% [33] - Sanhuan Group reported a revenue of 4.149 billion yuan, a year-on-year increase of 21.05%, and a net profit of 1.237 billion yuan, a year-on-year increase of 20.63% [35] - China Energy Construction achieved a revenue of 212.091 billion yuan, a year-on-year increase of 9.18%, and a net profit of 28.02 billion yuan, a year-on-year increase of 0.72% [37] Group 9 - Liou Co., Ltd. reported a revenue of 9.635 billion yuan, a year-on-year decrease of 9.62%, and a net profit of 478 million yuan, turning from a loss to profit [38] - Suzhou Bank achieved a revenue of 6.504 billion yuan, a year-on-year increase of 1.81%, and a net profit of 3.134 billion yuan, a year-on-year increase of 6.15% [40] - Shunxin Agriculture reported a revenue of 4.593 billion yuan, a year-on-year decrease of 19.24%, and a net profit of 173 million yuan, a year-on-year decrease of 59.09% [43] Group 10 - Tongfu Microelectronics achieved a revenue of 13.038 billion yuan, a year-on-year increase of 17.67%, and a net profit of 412 million yuan, a year-on-year increase of 27.72% [44] - Weidao Nano reported a revenue of 1.05 billion yuan, a year-on-year increase of 33.42%, and a net profit of 192 million yuan, a year-on-year increase of 348.95% [44] - ZTE Corporation achieved a revenue of 715.53 billion yuan, a year-on-year increase of 14.51%, and a net profit of 50.58 billion yuan, a year-on-year decrease of 11.77% [46]

Core Viewpoint - The global healthcare industry is facing significant uncertainties in 2025, yet Mindray Medical has demonstrated resilience and growth, particularly in its international business, which has helped mitigate domestic market fluctuations [1][2]. Financial Performance - In the first half of 2025, Mindray Medical achieved revenue of 16.743 billion yuan and a net profit of 5.069 billion yuan, with earnings per share of 4.1840 yuan [2]. - The company plans to distribute a cash dividend of 13.10 yuan per 10 shares, totaling 1.588 billion yuan, reflecting its commitment to shareholder returns [2]. - The company anticipates positive revenue growth in Q3 2025, with improvements in both international and domestic markets [2]. Business Segments - The in-vitro diagnostics (IVD) segment has become the largest revenue source, generating 6.424 billion yuan in the first half of 2025, with significant growth in international markets [4]. - The life information and support segment reported revenue of 5.479 billion yuan, with international revenue accounting for 67%, indicating increased global brand recognition [4]. - The medical imaging segment generated 3.312 billion yuan, with international revenue comprising 62%, and the high-end ultrasound series showing rapid growth [5]. Digital Transformation - Mindray is undergoing a digital transformation, focusing on "AI + healthcare," with the global AI healthcare market projected to exceed $100 billion by 2028 [6]. - The company has established a digital healthcare ecosystem integrating devices, IT, and AI, enhancing its service offerings and customer value [10]. Business Model Evolution - Mindray is shifting from traditional equipment sales to a "device + high-value consumables + software services" recurring revenue model, which is becoming a key growth driver [13]. - The company has strengthened its capabilities through acquisitions, enhancing its product offerings and market presence [13]. - Software and services are increasingly vital to the new business model, with plans to expand AI applications across various medical scenarios [14]. Strategic Outlook - Despite challenges in the global medical device industry, Mindray is proactively pursuing growth through digital transformation and redefining its business boundaries [15]. - The company is positioned not just as a domestic alternative but as a leading player in the global medical technology arena, driven by innovation and globalization [16].